Compare AbCellera Biologics Inc (ABCL) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Smith & Nephew plc — how do they compare? AbCellera Biologics Inc trades at $9.22 (market cap $2.99B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 4.2× AbCellera Biologics Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SNN | |
|---|---|---|
Market Cap | $2.99B | $12.54B |
Sector | Health | Health |
52-Week High | $9.76 | $38.70 |
52-Week Low | $2.78 | $28.73 |
Enterprise Value | $2.58B | $15.57B |
Dividend Yield | — | 2.65% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
